Study of INV-102 Ophthalmic Solution in Adults With Moderate Symptomatic Dry Eye Disease
Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
Phase 1/2, first-in-human, 2-part study to assess topically administered eyedrops of INV-102
during 2-week repeat dosing in subjects with moderate symptomatic dry eye disease. Part 1
will be a Dose Escalation phase across 4 cohorts of subjects to assess safety and
tolerability of INV-102, and Part 2 will be an Optional Dose Expansion phase in a fifth
cohort of subjects, pending the outcome of Part 1, to assess efficacy of INV-102 in the
treatment of moderate symptomatic dry eye disease.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Invirsa, Inc.
Collaborator:
Biomedical Advanced Research and Development Authority